A PHASE 1 DOSE ESCALATION STUDY OF A NEW ALK INHIBITOR, CH5424802/RO5424802, IN ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO HAVE FAILED CRIZOTINIB (AF-002JG/NP28761, NCT01588028)
JOURNAL OF THORACIC ONCOLOGY（2013）
Key words
ALK-inhibitor,Crizotinib-failure,Phase I,CH5424802
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined